Gene info: ID 3106

Gene: HLA-B

GENE ID: 3106

Synonyms: AS|B-4901|HLAB

Description: major histocompatibility complex, class I, B

Gene type: protein-coding

Location: 6p21.33

dbXrefs: Ensembl:ENSG00000234745 MIM:142830 Vega:OTTHUMG00000031153 UniprotKB:P01889

RefSeq: NG_023187.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 14

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : NA (AD) NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
B2M	0.943
HLA-E	0.921
HLA-A	0.919
HLA-F	0.882
IFITM1	0.877
PSMB8	0.868
HLA-C	0.852
TAGLN2	0.847
MYL12A	0.846
SLC15A3	0.845

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F29	-0.514
OR4F5	-0.484
ADRA1D	-0.336
SLC7A4	-0.332
MARCH4	-0.33
MYADML2	-0.33
CALHM1	-0.326
ABCC12	-0.322
KCNB2	-0.317
PPEF1	-0.317

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C030370	2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone	"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of HLA-B mRNA"	20206263
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
C106538	abacavir	HLA-B gene polymorphism results in increased susceptibility to abacavir	11943262
C106538	abacavir	HLA-B protein affects the susceptibility to abacavir	15024131
C106538	abacavir	HLA-B protein polymorphism results in increased susceptibility to abacavir	23541086
C106538	abacavir	[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IFNG protein	23541086
C106538	abacavir	[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IL13 protein	23541086
C106538	abacavir	[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of TNF protein	23541086
C106538	abacavir	HLA-B gene polymorphism results in increased susceptibility to [CPG-oligonucleotide co-treated with abacavir]	29319822
D000082	Acetaminophen	Acetaminophen results in increased expression of HLA-B mRNA	26690555
C027955	aflatoxin G1	aflatoxin G1 results in decreased expression of HLA-B mRNA	20381597
D000447	Aldehydes	Aldehydes results in increased expression of HLA-B mRNA	25014914
D000493	Allopurinol	HLA-B gene polymorphism results in increased susceptibility to Allopurinol	15743917
D000658	Amoxicillin	Amoxicillin affects the expression of HLA-B mRNA	25811541
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of HLA-B mRNA	24449571
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of HLA-B mRNA	15725085\|1576101
C487081	belinostat	belinostat results in increased expression of HLA-B mRNA	27188386
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the expression of HLA-B mRNA	22342234
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of HLA-B mRNA"	20018196
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of HLA-B mRNA	19619570
D004958	Estradiol	Estradiol results in increased expression of HLA-B mRNA	19619570
C111827	brinzolamide	brinzolamide affects the expression of HLA-B mRNA	25811541
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of HLA-B mRNA	15336504
C018475	butyraldehyde	butyraldehyde results in increased expression of HLA-B mRNA	26079696
C584509	C646 compound	C646 compound results in increased expression of HLA-B mRNA	26191083
D002104	Cadmium	Cadmium results in increased expression of HLA-B mRNA	24376830
C028031	cadmium acetate	cadmium acetate results in increased expression of HLA-B mRNA	12965115
D002220	Carbamazepine	HLA-B gene polymorphism affects the susceptibility to Carbamazepine	18855540\|1969479
D002220	Carbamazepine	HLA-B gene SNP affects the susceptibility to Carbamazepine	16538176
D002434	Cefadroxil	Cefadroxil affects the expression of HLA-B mRNA	25811541
C018021	cobaltous chloride	cobaltous chloride results in increased expression of HLA-B mRNA	19320972\|1937684
D003300	Copper	[Disulfiram binds to Copper] which results in increased expression of HLA-B mRNA	24690739
C408982	CPG-oligonucleotide	HLA-B gene polymorphism results in increased susceptibility to [CPG-oligonucleotide co-treated with abacavir]	29319822
D004041	Dietary Fats	[Dietary Fats co-treated with resveratrol] results in decreased expression of HLA-B mRNA	21852083
D004041	Dietary Fats	resveratrol inhibits the reaction [Dietary Fats results in decreased expression of HLA-B mRNA]	21852083
D004110	Diltiazem	Diltiazem affects the expression of HLA-B mRNA	25811541
D004221	Disulfiram	[Disulfiram binds to Copper] which results in increased expression of HLA-B mRNA	24690739
D004318	Doxycycline	Doxycycline affects the expression of HLA-B mRNA	25811541
C118739	entinostat	entinostat results in increased expression of HLA-B mRNA	27188386
D004917	Erythromycin	Erythromycin affects the expression of HLA-B mRNA	25811541
D005047	Etoposide	Etoposide affects the expression of HLA-B mRNA	25811541
D005054	Eugenol	Eugenol results in increased expression of HLA-B mRNA	17374397
D005436	Floxacillin	HLA-B gene polymorphism affects the susceptibility to Floxacillin	19483685
D005665	Furosemide	Furosemide affects the expression of HLA-B mRNA	25811541
D006046	Gold	HLA-B gene polymorphism affects the susceptibility to Gold	3084782
D006830	Hydralazine	[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-B mRNA	17183730
C492448	ICG 001	ICG 001 results in increased expression of HLA-B mRNA	26191083
D007069	Ifosfamide	Ifosfamide affects the expression of HLA-B mRNA	25811541
C051890	irinotecan	irinotecan analog results in decreased expression of HLA-B mRNA	18927307
C047781	lamotrigine	HLA-B gene polymorphism affects the susceptibility to lamotrigine	20235791\|2048515
D008095	Lithocholic Acid	Lithocholic Acid results in decreased expression of HLA-B mRNA	8196671
C053091	lomefloxacin	lomefloxacin affects the expression of HLA-B mRNA	25811541
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of HLA-B mRNA	28001369
D008788	Metolazone	Metolazone affects the expression of HLA-B mRNA	25811541
D008911	Minocycline	Minocycline affects the expression of HLA-B mRNA	25811541
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of HLA-B protein	24625837
C523799	MRK 003	MRK 003 results in decreased expression of HLA-B mRNA	21169257
C029938	nickel sulfate	nickel sulfate results in increased expression of HLA-B mRNA	17374397
C025589	ochratoxin A	ochratoxin A results in increased acetylation of HLA-B promoter	29098329
C025589	ochratoxin A	[ochratoxin A results in increased acetylation of HLA-B promoter] which results in increased expression of HLA-B mRNA	29098329\|2909832
C025589	ochratoxin A	ochratoxin A results in increased expression of HLA-B mRNA	29098329
D009853	Omeprazole	Omeprazole affects the expression of HLA-B mRNA	25811541
D010081	Oxazolone	Oxazolone results in increased expression of HLA-B mRNA	17374397
C036006	oxcarbazepine	HLA-B gene polymorphism affects the susceptibility to oxcarbazepine	20235791
D010396	Penicillamine	HLA-B gene polymorphism affects the susceptibility to Penicillamine	3437418\|3459889\|
C046012	pentanal	pentanal results in increased expression of HLA-B mRNA	26079696
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of HLA-B mRNA	26272509
D010672	Phenytoin	HLA-B gene polymorphism affects the susceptibility to Phenytoin	20235791
D010894	Piroxicam	Piroxicam affects the expression of HLA-B mRNA	25811541
C005556	propionaldehyde	propionaldehyde results in increased expression of HLA-B mRNA	26079696
D011794	Quercetin	Quercetin results in increased expression of HLA-B	20386467
C059514	resveratrol	[Dietary Fats co-treated with resveratrol] results in decreased expression of HLA-B mRNA	21852083
C059514	resveratrol	resveratrol inhibits the reaction [Dietary Fats results in decreased expression of HLA-B mRNA]	21852083
D012643	Selenium	Selenium results in increased expression of HLA-B mRNA	19244175
C017947	sodium arsenite	sodium arsenite results in decreased expression of HLA-B mRNA	25879800
C017947	sodium arsenite	sodium arsenite results in decreased expression of HLA-B protein	20050688
D013467	Sulindac	Sulindac affects the expression of HLA-B mRNA	25811541
D013629	Tamoxifen	Tamoxifen affects the expression of HLA-B mRNA	25811541
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of HLA-B mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of HLA-B mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of HLA-B mRNA	20106945\|2163298
D013849	Thimerosal	Thimerosal results in decreased expression of HLA-B mRNA	27188386
D008625	Tiopronin	HLA-B gene polymorphism affects the susceptibility to Tiopronin	3084782
D014212	Tretinoin	Tretinoin results in increased expression of HLA-B mRNA	15894607\|1721838
C012589	trichostatin A	trichostatin A results in increased expression of HLA-B mRNA	24935251\|2718838
D014635	Valproic Acid	[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-B mRNA	17183730
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-B mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of HLA-B mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased methylation of HLA-B gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of HLA-B mRNA	19101580\|2317975
D014640	Vancomycin	Vancomycin affects the expression of HLA-B mRNA	25811541
D014810	Vitamin E	Vitamin E results in increased expression of HLA-B mRNA	19244175
C111237	vorinostat	vorinostat results in increased expression of HLA-B mRNA	27188386
D015215	Zidovudine	Zidovudine affects the expression of HLA-B mRNA	25811541

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005102	signaling receptor binding	-	IBA	21873635
GO:0005515	protein binding	-	IPI	18322206 19858347
GO:0042605	peptide antigen binding	-	IBA	21873635
GO:0042605	peptide antigen binding	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001916	positive regulation of T cell mediated cytotoxicity	-	IBA	21873635
GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	-	IBA	21873635
GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	-	TAS	-
GO:0002476	antigen processing and presentation of endogenous peptide antigen via MHC class Ib	-	IBA	21873635
GO:0002479	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	-	TAS	-
GO:0002480	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent	-	TAS	-
GO:0006955	immune response	-	IBA	21873635
GO:0016032	viral process	-	IEA	-
GO:0050776	regulation of immune response	-	TAS	-
GO:0060333	interferon-gamma-mediated signaling pathway	-	TAS	-
GO:0060337	type I interferon signaling pathway	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000139	Golgi membrane	-	TAS	-
GO:0005783	endoplasmic reticulum	-	ISS	-
GO:0005794	Golgi apparatus	-	ISS	-
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	TAS	-
GO:0009986	cell surface	-	ISS	-
GO:0012507	ER to Golgi transport vesicle membrane	-	TAS	-
GO:0030670	phagocytic vesicle membrane	-	TAS	-
GO:0031901	early endosome membrane	-	TAS	-
GO:0042612	MHC class I protein complex	-	ISS	-
GO:0055038	recycling endosome membrane	-	TAS	-
GO:0071556	integral component of lumenal side of endoplasmic reticulum membrane	-	TAS	-

KEGG ID	KEGG Term
hsa04144	Endocytosis
hsa04145	Phagosome
hsa04514	Cell adhesion molecules (CAMs)
hsa04612	Antigen processing and presentation
hsa04650	Natural killer cell mediated cytotoxicity
hsa04940	Type I diabetes mellitus
hsa05320	Autoimmune thyroid disease
hsa05330	Allograft rejection
hsa05332	Graft-versus-host disease
hsa05416	Viral myocarditis

Reactome ID	Reactome Term	Evidence
R-HSA-1236974	ER-Phagosome pathway	TAS
R-HSA-1236974	ER-Phagosome pathway	IEA
R-HSA-1236975	Antigen processing-Cross presentation	TAS
R-HSA-1236975	Antigen processing-Cross presentation	IEA
R-HSA-1236977	Endosomal/Vacuolar pathway	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-1280218	Adaptive Immune System	IEA
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-168256	Immune System	IEA
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	TAS
R-HSA-6798695	Neutrophil degranulation	TAS
R-HSA-877300	Interferon gamma signaling	TAS
R-HSA-909733	Interferon alpha/beta signaling	TAS
R-HSA-913531	Interferon Signaling	TAS
R-HSA-983169	Class I MHC mediated antigen processing & presentation	IEA
R-HSA-983169	Class I MHC mediated antigen processing & presentation	TAS
R-HSA-983170	Antigen Presentation: Folding, assembly and peptide loading of class I MHC	IEA
R-HSA-983170	Antigen Presentation: Folding, assembly and peptide loading of class I MHC	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
2178463	Early onset of nonalcoholic cirrhosis in patients with familial alcoholism. (1990 Feb)	Arria AM	Alcohol Clin Exp Res
26339134	HLA Haplotypes and Genotypes Frequencies in Brazilian Chronic Periodontitis Patients. (2015)	Sippert EA	Mediators Inflamm
1373340	Do histocompatibility antigens influence the risk of head and neck carcinoma? (1992 May 1)	Houck JR	Cancer
23395714	Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. (2013 Aug)	Sinkus ML	Brain Behav Immun
8740767	HLA*A2 confers mortality risk for cardiovascular disease in Pimans. (1996 Mar)	Williams RC	Tissue Antigens
18589099	HLA polymorphisms as incidence factor in the progression to end-stage renal disease in Brazilian patients awaiting kidney transplant. (2008 Jun)	Crispim JC	Transplant Proc
22443520	Individual composition of human leukocyte antigens and periodontopathogens in the background of periodontitis. (2013 Jan)	Reichert S	J Periodontol
6788410	Genetic factors in determining susceptibility to alcohol dependence and development of alcohol-induced liver disease. (1981 May)	Jenkins WJ	Clin Gastroenterol
26098791	Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis. (2015 Oct)	Kim K	Arthritis Rheumatol
17212707	Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease. (2007 Jan)	Palikhe A	Tissue Antigens
19565552	Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. (2009 Jul 15)	Ward MM	Arthritis Rheum
21883488	The prevalence of dysplasia and malignant lip lesions in transplant patients. (2012 Feb)	Nolan A	J Oral Pathol Med
6708601	A study of HLA antigens in alcoholism. (1984 Apr)	Robertson DM	Mayo Clin Proc
9479594	Lower frequency of sister chromatid exchanges and altered frequency of HLA B-region alleles among individuals with sporadic dysplastic nevi. (1997 Jul-Sep)	Illeni MT	Int J Biol Markers